The association of other active drugs or substances with benznidazole (BZ) or nifurtimox (NF) has been stimulated to treat Chagas disease (CD) since these drugs present limitations. As the dog is an excellent model for Chagas disease study and its treatment, our study explored the association of BZ with the itraconazole (ITZ) in dogs infected with a Trypanosoma cruzi strain resistant to BZ and NF, treated at the acute and chronic phases of the infection. BZ+ITZ treatment reduced parasitemia, hemoculture, PCR positivity, cardiac inflammation, fibrosis, qPCR positivity, and mortality during the acute phase. During the chronic phase, a less severe reduction of the same parameters was observed, but the echocardiography revealed reduction on disease evolution. The pharmacokinetics of the Drug’s association was more advantageous for CD treatment than the monotherapy since benznidazole exposition was higher.
Marta de Lana: Brazilian, Emeritus Professor at the Federal University of Ouro Preto. Member of the Brazilian Academy of Pharmaceutical Sciences. Pharmacist, M.S., and Ph.D. in Parasitology at the Federal University of Minas Gerais. Postdoctoral program at the IRD, France. Professor of Clinical Parasitology at the Pharmacy School, UFOP since 1982, Director of the Pharmacy School and Head of Animal Care Facilities, UFOP. Recipient of a scholarship from the National Council for Scientific and Technological Development (CNPq). Advisor and professor in the Biological Sciences and Pharmaceutical Sciences Graduate programs, UFOP. Member of the Biological Sciences and Biotechnology and Member of the Health Sciences Committees, respectively, at the Foundation for Research Support (FAPEMIG). Institutional Coordinator of the State Network for Research on Pharmacological and Toxicological Tests of Drugs, Therapeutic Products, and Raw Materials, and the State Network for the Animal Care Facilities (FAPEMIG).